These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30362279)

  • 1. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
    Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
    HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM).
    Liégeois F; Boyer S; Eymard-Duvernay S; Carrieri P; Kouanfack C; Domyeum J; Maradan G; Ducos J; Mpoudi-Ngolé E; Spire B; Delaporte E; Kuaban C; Vidal L; Laurent C;
    BMC Infect Dis; 2020 Jan; 20(1):49. PubMed ID: 31941464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
    Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
    Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
    Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
    AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
    J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey.
    Marinda E; Simbayi L; Zuma K; Zungu N; Moyo S; Kondlo L; Jooste S; Nadol P; Igumbor E; Dietrich C; Briggs-Hagen M
    BMC Public Health; 2020 Sep; 20(1):1375. PubMed ID: 32907565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey.
    Huerga H; Van Cutsem G; Ben Farhat J; Puren A; Bouhenia M; Wiesner L; Dlamini L; Maman D; Ellman T; Etard JF
    BMC Public Health; 2018 Mar; 18(1):303. PubMed ID: 29499668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon.
    Fokam J; Nangmo A; Wandum C; Takou D; Santoro MM; Nlend AN; Ateba FN; Ndombo PK; Kamgaing N; Kamta C; Essiane A; Lambo V; Fokunang C; Mbanya D; Colizzi V; Perno CF; Ndjolo A
    AIDS Res Ther; 2020 May; 17(1):14. PubMed ID: 32398107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey.
    Fiorentino M; Sagaon-Teyssier L; Ndiaye K; Suzan-Monti M; Mengue MT; Vidal L; Kuaban C; March L; Laurent C; Spire B; Boyer S;
    Womens Health (Lond); 2019; 15():1745506519848546. PubMed ID: 31177929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.
    Desta AA; Woldearegay TW; Futwi N; Gebrehiwot GT; Gebru GG; Berhe AA; Godefay H
    BMC Infect Dis; 2020 Jan; 20(1):4. PubMed ID: 31898535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.
    Gaolathe T; Wirth KE; Holme MP; Makhema J; Moyo S; Chakalisa U; Yankinda EK; Lei Q; Mmalane M; Novitsky V; Okui L; van Widenfelt E; Powis KM; Khan N; Bennett K; Bussmann H; Dryden-Peterson S; Lebelonyane R; El-Halabi S; Mills LA; Marukutira T; Wang R; Tchetgen EJ; DeGruttola V; Essex M; Lockman S;
    Lancet HIV; 2016 May; 3(5):e221-30. PubMed ID: 27126489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal.
    Byabene AK; Fortes-Déguénonvo L; Niang K; Manga MN; Bulabula ANH; Nachega JB; Seydi M
    Trop Med Int Health; 2017 Jun; 22(6):776-782. PubMed ID: 28407436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B.
    Atanga PN; Ndetan HT; Fon PN; Meriki HD; Muffih TP; Achidi EA; Hoelscher M; Kroidl A
    BMC Pregnancy Childbirth; 2018 Oct; 18(1):418. PubMed ID: 30359239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
    BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
    Ntamatungiro AJ; Muri L; Glass TR; Erb S; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E;
    J Antimicrob Chemother; 2017 Jul; 72(7):2069-2074. PubMed ID: 28387865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
    Girometti N; Lander F; McOwan A; Nwokolo N; Boffito M; Whitlock G;
    HIV Med; 2020 Oct; 21(9):613-615. PubMed ID: 32869951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
    Fatti G; Shaikh N; Eley B; Grimwood A
    AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.